APEX2

Across TCGA pan-cancer cohorts, APEX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APEX2 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APEX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APEX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where APEX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.633	0.915	.011	7	view →
LUAD	DFS	Tertile	III,IV	0.916	0.375	.024	3	view →
UCEC	DFS	Quartile	All	1.000	0.861	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

APEX2–CCRCC (DFS)

Open the CCRCC breakdown →